Почетна › Многи мијелом › Тенеси
Kliničke studije za Многи мијелом u državi Тенеси
31 studija za Многи мијелом traži učesnike na lokacijama u državi Тенеси.
Gradovi u državi Тенеси
Zvanični tekst studije (na engleskom)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06152575A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT05650632A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07589634A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Henry-Joyce Cancer Clinic, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07258511A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07284758A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT05651932A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- SCRI Oncology Partners /ID# 278353, Nashville
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07095452A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT07681596AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Nashville
- Research Site, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, PLLC, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07073547A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT02693535A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 9. 2026. · NCT07637578Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 8. 2026. · NCT06375044A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT07227311A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chattanooga
- GSK Investigational Site, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 8. 2026. · NCT05714839Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
- Vanderbilt University Medical Center, Nashville
Тражи се учесникФаза 2
Узраст од 18 до 70 · Оба пола · Ажурирано 19. 8. 2026. · NCT07485647A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT06292780Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Nashville
- Research Site, Nashville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 8. 2026. · NCT07764978A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 7. 2026. · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 2
Узраст 19 и старији · Оба пола · Ажурирано 4. 6. 2026. · NCT06974786Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 4. 2026. · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- TriStar Centennial Medical Center, Nashville
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 3. 2026. · NCT06153251CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2025. · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- SCRI Oncology Partners, Nashville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 6. 2025. · NCT06119685Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.